ORALS

Nicotinamide adenine dinucleotide (NAD+) is involved in regulating various biological processes and decreased with aging or oxidative stress [1]. Nicotinamide mononucleotide (NMN) increases intracellular NAD+ levels and counteracts age-associated changes [2,3]. We investigated the safety and efficacy of oral NMN supplementation (250 mg/day) in older diabetic patients with impaired physical performance.<br />We conducted a 24-week placebo-controlled, double-blind study for male diabetic patients aged 65 years or older with reduced grip strength (less than 26 kg) or reduced walking speed (lenn than 1.0 m/sec). We studied 14 participants aged 81.1±6.4 years. NMN was tolerable without any related severe adverse events. The changes in grip strength and walking speed showed no difference between the two groups; However, there were trends toward an improved prevalence of frailty in the NMN group (p=0.066) and different changes in central retinal thickness between the two groups (P=0.051). <br />In conclusion, in the present study performed on older male diabetic patients with physically impaired performance, a 24-week administration of 250 mg NMN was safe. Still, it did not affect grip strength or walking speed. However, a subanalysis indicated that NMN has the potential to improve frailty status and central retinal thickness. Directions to improve frailty and retinal thickness with NMN may be a further expected issue to be investigated.

References:
[1] Gomes AP, Price NL, Ling AJ, Moslehi JJ, Montgomery MK, Rajman L, White JP, Teodoro JS, Wrann CD, Hubbard BP, Mercken EM, Palmeira CM, de Cabo R, Rolo AP, Turner N, Bell EL, Sinclair DA. Cell 2013; 155: 1624-1638.\n[2] Yoshino J, Mills KF, Yoon MJ, Imai SI. Cell Metab 2011; 14: 528-536.\n[3] Yoshino M, Yoshino J, Kayser BD, Patti GJ, Franczyk MP, Mills KF, Sindelar M, Pietka T, Patterson BW, Imai SI, Klein S. Science 2021; 372: 1224-1229.